Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival

Ishikawa, Toru; Kubota, Tomoyuki; Abe, Satoshi; Watanabe, Y.; Sugano, Tomoyuki; Inoue, Ryousuke; Iwanaga, Akito; Seki, Keiichi; Honma, Teruki; Yoshida, Toshiaki

doi:10.1093/annonc/mdu155

Cited by 16 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ishikawa et al [46] compared the survival rates of patients who received RFA with or without prior HAIC (DDP-H). Cumulative survival rates at 1, 3, and 5 years were 77.4%, 69.2%, and 55.3% for RFA alone, respectively, and 97.4%, 87.0%, and 84.4% for prior HAIC + RFA, respectively.…”

Section: Neo-adjuvant Therapymentioning

confidence: 99%

Current Status of Hepatic Arterial Infusion Chemotherapy

Obi

Sato

Kawai³

2015

Liver Cancer

105

View full text Add to dashboard Cite

Background: Hepatic arterial infusion chemotherapy (HAIC) is frequently used to treat advanced hepatocellular carcinoma (HCC) in Asian countries. However, there is a lack of evidence supporting the use of HAIC. Summary: Many studies report high response rates in patients with advanced HCC receiving HAIC, and clinical responses translate to survival benefits. Therefore, prediction of an antitumor response is important in selecting appropriate treatments. There are no proven post-sorafenib therapeutic measures or procedures for HCC patients with poor liver function, and HAIC is one of the few options for patients in these situations. Despite studies showing its effectiveness, the use of HAIC for treatment of advanced HCC is unclear because convincing data from large-scale randomized clinical trials are lacking. For HAIC to become a standard treatment for HCC, such trials must establish its efficacy compared with other HCC therapies; prediction of antitumor response in HAIC may aid trial design, and a multi-center, open-labelled, randomized clinical trial of HAIC in advanced HCC is currently in progress. Optimization of HCC treatment protocols and regimens is also required. Key message: We think that both HAIC and sorafenib are effective treatments for advanced HCC, and this review presents evidence supporting this contention.

show abstract

Section: Neo-adjuvant Therapymentioning

confidence: 99%

Current Status of Hepatic Arterial Infusion Chemotherapy

Obi

Sato

Kawai³

2015

Liver Cancer

105

View full text Add to dashboard Cite

show abstract

“…AST: aspartate aminotransferase; ALT: alanine aminotransferase; AFP: alpha-fetoprotein; POD: post-operative day; POM: post-operative month The regimen selected for this study was 2 weeks of low-dose FP. Ishikawa et al [29,30] first reported that HAIC with cisplatin before radical local treatment (radiofrequency ablation/percutaneous ethanol injection therapy) for early-stage HCC prevented intrahepatic metastasis and prolonged the survival time. According to some clinical studies, the efficacy of low-dose FP is better than that of cisplatin alone [28] .…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant hepatic arterial infusion chemotherapy for resectable hepatocellular carcinomas

Tsutsui¹,

Nagamatsu²,

Itano³

et al. 2018

View full text Add to dashboard Cite

Aim: To evaluate the effect of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) on the survival of patients with resectable hepatocellular carcinoma (HCC). Methods: Between January 2003 and January 2014, 80 patients underwent hepatic resection for HCC. Of these patients, we evaluated 49 patients who met the following inclusion criteria: (1) preserved liver function (Child-Pugh A); (2) resectable HCC (≤ 3 nodules, regardless of the size); and (3) HCC with high-grade malignant potential. Among them, 13 patients underwent neoadjuvant HAIC and curative hepatectomy (treatment group). The remaining 36 patients underwent curative hepatic resection without neoadjuvant therapy (control group). Survival after hepatic resection was compared retrospectively between the groups. Results: During follow-up, 2 (15.4%) patients in the treatment group and 25 (69.4%) patients in the control group developed recurrence. The 1-, 3-, and 5-year disease-free rates (100%, 78.6%, and 78.6%, respectively vs. 65.8%, 33.7%, and 26.6%, respectively; P = 0.003) and overall survival rates (100%, 100%, and 100%, respectively vs. 91.7%, 77.8%, and 55.3%, respectively; P = 0.037) were significantly better in the treatment group than in the control group. Conclusion: Neoadjuvant HAIC decreased the risk of recurrence and improved survival in patients with HCC with high malignant potential.

show abstract

“…When we investigated the effect of the addition of TAI with DDP-H and carboplatin as pretreatment prior to TACE/radiofrequency ablation therapy as radical local treatment for stage I/II HCC, we reported that whole-liver TAI using DDP-H significantly inhibited intrahepatic recurrence (9). In addition, in patients with JIS 0–1 stage HCC, survival was significantly prolonged in the group that received whole-liver TAI with DDP-H compared with the group that did not undergo infusion, and the results of the multivariate analyses demonstrated that performing whole-liver TAI with DDP-H was a factor contributing to improved survival (10). Kim et al conducted a retrospective study on the efficacy of arterial cisplatin infusion following TACE in advanced HCC with hepatic vein invasion, and reported that, in the group of patients who underwent arterial cisplatin infusion, survival was significantly prolonged without increased adverse events, compared with that in patients who did not undergo infusion (13).…”

Section: Discussionmentioning

confidence: 99%

“…We previously reported that whole-liver transcatheter arterial infusion (TAI) with a high concentration of a fine-powder formulation of cisplatin (DDP-H) (IA-call ® ; Nippon Kayaku Co. Ltd., Tokyo, Japan) prior to radical local treatment inhibited intrahepatic recurrence of HCC (9), and that whole-liver TAI of DDP-H administered to HCC patients with a Japan Integrated Staging (JIS) score of 0–1 improved survival (10). …”

Section: Introductionmentioning

confidence: 99%

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma

Ishikawa

Abe

Watanabe

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Transcatheter arterial chemoembolization (TACE) is the standard therapy for Barcelona Clinic Liver Cancer (BCLC) classification intermediate stage B hepatocellular carcinoma (HCC). However, other transcatheter methods, such as transcatheter arterial infusion (TAI), also play an important role in the treatment of advanced HCC. Although it has been reported that TAI with a high concentration of a fine-powder formulation of cisplatin (DDP-H) reduced intrahepatic recurrence and improved survival, the combined use of TAI with DDP-H and TACE has not yet been investigated. The aim of this study was to evaluate which TACE chemotherapeutic agent in combination with DDP-H TAI contributes more to improved survival in BCLC-B HCC. Survival was analyzed in 55 patients who underwent DDP-H TAI and TACE for BCLC-B HCC. The patients were classified into two groups; Epirubicin was used as the TACE agent in 29 patients, whereas miriplatin was used in 26 patients. The cumulative survival rates at 1 and 2 years were 66.4 and 36.0% in the epirubicin and 95.8 and 61.30% in the miriplatin group, respectively. Survival time was significantly prolonged in the miriplatin group compared with that in the epirubicin group. Multivariate analysis identified Child-Pugh classification and up-to-seven criteria as factors affecting survival. In addition, the selection of miriplatin as the TACE chemoagent was the treatment factor that most significantly affected survival. Thus, double-platinum therapy with DDP-H TAI and miriplatin TACE may be a useful treatment strategy for improving survival in BCLC-B HCC patients.

show abstract

Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival

Cited by 16 publications

References 15 publications

Current Status of Hepatic Arterial Infusion Chemotherapy

Current Status of Hepatic Arterial Infusion Chemotherapy

Neoadjuvant hepatic arterial infusion chemotherapy for resectable hepatocellular carcinomas

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma

Contact Info

Product

Resources

About